10x Genomics, Inc. (TXG)
After hours:
| Previous close | 19.92 |
| Open | 20.15 |
| Bid | 20.20 x 1200 |
| Ask | 20.26 x 600 |
| Day's range | 19.71 - 20.80 |
| 52-week range | 15.28 - 63.57 |
| Volume | |
| Avg. volume | 1,909,533 |
| Market cap | 2.42B |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible fr
- PR Newswire
New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate. The study was led by researchers at the National Institutes of Health (NIH) in collaboration with computational experts at the University of Connecticut's Schools of Medicine and Dental Medicine.
- PR Newswire
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
